By the Manufacturing, Science, and Technology (MS&T) team at Kymanox Corporation

Maintaining a robust, reliable supply chain is crucial for companies manufacturing Cell and Gene Therapies (CGTs) to reduce risk of delays and ensure the stability and efficacy of time and temperature sensitive materials. Supply chain disruptions over the past years and the CGT industry’s reliance on a combination of single use products and stainless steel, complex manufacturing practices, and regulatory complexity create unique demands when compared to other industries.

Read More